Quincy Bioscience receives investment
This article was originally published in The Tan Sheet
Executive Summary
A capital infusion from the investment group DaneVest Tech Fund I will help Quincy Bioscience market its "novel" dietary supplement Prevagen, the Madison, Wis.-based biotech announces Aug. 25. Quincy launched the brain cell protection supplement in 2007 and says the unquantified investment "will accelerate our goal to make Prevagen a national brand" (1"The Tan Sheet" Aug. 10, 2009). Prevagen's active ingredient apoaequorin comes from jellyfish and is a calcium-binding protein that helps buffer excess calcium from damaging aging neurons, Quincy says